Peter Voorhees, MD of Levine Cancer Institute addresses phase 2 GRIFFIN study affecting clinicians and treatment today. _______ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone. The data, selected as a late-breaking abstract, were presented at the 17th International Myeloma Workshop (IMW) meeting in Boston. “The GRIFFIN study is the second randomized…
Author: Editor
Peter Voorhees, MD of Levine Cancer Institute answers questions received from the audience at IMW 2019 regarding the phase 2 GRIFFIN study patients with high risk cytogenetics. ______ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone. The data, selected as a late-breaking abstract, were presented at the 17th International Myeloma Workshop (IMW)…
Peter Voorhees, MD of Levine Cancer Institute answers commonly asked questions by colleagues regarding the phase 2 GRIFFIN study: should you change clinical practice or transplant newly diagnosed MM patients? _______ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone. The data, selected as a late-breaking abstract, were presented at the 17th International…
Peter Voorhees, MD of Levine Cancer Institute explains how the phase 2 GRIFFIN study shows a high response rate in patients with newly diagnosed MM. ________ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone. The data, selected as a late-breaking abstract, were presented at the 17th International Myeloma Workshop (IMW) meeting in…
COG study shows treatment can be reduced without compromising outcomes Study shows therapy can be reduced in some neuroblastoma patients Algorithm based on tumor biology, anticipated response to treatment For patients with localized tumors, 3-year overall survival was 100% BUFFALO, N.Y. — A recent Children’s Oncology Group (COG) study identified a treatment algorithm that can help reduce therapy for some neuroblastoma patients with intermediate-risk disease, while maintaining good clinical outcomes. The study’s findings are particularly significant because they suggest that many infants and young children with this disease may be spared unpleasant or lingering side effects of prolonged therapy, says…
Ashley T. Freeman, MD of BC Cancer explains how the idea that higher patient volumes are associated with longer survival in multiple myeloma will affect clinicians. _________ New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers. New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience. In general, providers who saw the most cases were more likely to be located at academic, NCI-designated cancer centers. However, the researchers…
Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and who progressed within 12 months on an androgen receptor (AR)-targeted agent (abiraterone or enzalutamide) experienced significantly longer radiographic progression free survival (rPFS) with Jevtana® (cabazitaxel) plus prednisone compared with abiraterone plus prednisone or enzalutamide. Overall survival (OS) with Jevtana was also significantly longer. These findings from the CARD study were presented today in the Presidential Symposium of the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.  “In this study, treatment with Jevtana significantly improved radiographic progression…
September 28, 2019  Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)  First glutaminase inhibitor to demonstrate clinical activity for treatment of cancer  SOUTH SAN FRANCISCO, Calif., Sept. 28, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, presented today supporting data for its previously reported positive results from its…
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019 and simultaneously published in Annals of Oncology  BARCELONA, Spain, Sept. 27, 2019 /PRNewswire/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated, longer-term results from the pivotal Phase 3 SPARTAN study following a second interim analysis. Treatment with ERLEADA® (apalutamide) plus androgen deprivation therapy (ADT) resulted in a 25 percent reduction in the risk of death compared with placebo plus ADT in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1  The updated findings showed…
Ashley T. Freeman, MD of BC Cancer explains commonly asked questions by colleagues: why do myeloma patients seem to do better when they are treated at a high volume facility or by high volume myeloma oncologist? _______ New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers. New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience. In general, providers who saw the most cases were more likely to…
Ashley T. Freeman, MD of BC Cancer provides insight on a study in JNCCN that supports the idea that higher patient volumes are associated with longer survival in MM. _________ New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers. New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience. In general, providers who saw the most cases were more likely to be located at academic, NCI-designated cancer centers.…
Analyses from the Phase III JAVELIN Renal 101 study support efficacy of BAVENCIO plus axitinib across multiple subgroups of patients with advanced renal cell carcinoma (RCC) Abstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the treatment of advanced cancers, including renal cell carcinoma (RCC), metastatic Merkel cell carcinoma (mMCC) and some other solid…
Anurag Singh, MD of Roswell Park explains what’s next in research. ______ Roswell Park researchers present findings at ASTRO Annual Meeting Aspirin improved overall survival for patients with head/neck, lung cancers Patients in both studies also received radiation or chemoradiation therapy Future studies will help determine which patients benefit most  BUFFALO, N.Y. — What if a drug that sits in nearly everyone’s medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting in Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. The results show significant improvements in overall survival (OS) and objective response rates (ORR) for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the efficacy and safety of the BRAFTOVI Triplet compared to the BRAFTOVI Doublet. These data will be presented…
Anurag Singh, MD of Roswell Park explains a commonly asked question by colleagues: why is there no benefit to cancer specific survival? _______ Roswell Park researchers present findings at ASTRO Annual Meeting Aspirin improved overall survival for patients with head/neck, lung cancers Patients in both studies also received radiation or chemoradiation therapy Future studies will help determine which patients benefit most  BUFFALO, N.Y. — What if a drug that sits in nearly everyone’s medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting in Chicago,…
Michael Buckstein, MD of Mount Sinai answers commonly asked questions by his colleagues: are you overtreating the patients? What is our toxicity profile? How often do patients recur after the treatments? ______ Preliminary results from this Phase II trial show very promising response rates when combining TACE+SBRT in large, unresectable HCC with excellent OS, PFS, and CSS. These preliminary data are currently being confirmed in an expanded cohort.
Anurag Singh, MD of Roswell Park reveals that patients with some cancers who have taken baby aspirin can improve overall survival. ________ Roswell Park researchers present findings at ASTRO Annual Meeting Aspirin improved overall survival for patients with head/neck, lung cancers Patients in both studies also received radiation or chemoradiation therapy Future studies will help determine which patients benefit most  BUFFALO, N.Y. — What if a drug that sits in nearly everyone’s medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting in Chicago, doctors…
Michael Buckstein, MD of Mount Sinai explains the Phase II trial using combination of TACE and SBRT for unresectable single large HCC. ________ Preliminary results from this Phase II trial show very promising response rates when combining TACE+SBRT in large, unresectable HCC with excellent OS, PFS, and CSS. These preliminary data are currently being confirmed in an expanded cohort.
William Smith, MD of Mount Sinai addresses the next steps in radiation therapy on the objective response and outcomes in nivolumab for hepatocellular carcinoma. _____ Among patients with unresectable hepatocellular carcinoma who received combination upfront RT and nivolumab, we found the objective response rate (as determined by mRECIST criteria) to be 35%, substantially increased from historical controls, suggesting that this approach may increase the proportion of patients that would benefit from immune checkpoint inhibition.
William Smith, MD of Mount Sinai explains how this affects clinicians today? _______ Among patients with unresectable hepatocellular carcinoma who received combination upfront RT and nivolumab, we found the objective response rate (as determined by mRECIST criteria) to be 35%, substantially increased from historical controls, suggesting that this approach may increase the proportion of patients that would benefit from immune checkpoint inhibition.
William Smith, MD of Mount Sinai answers multiple questions received from colleagues, including: when did patients receive radiation relevant to nivolumab? ______ Among patients with unresectable hepatocellular carcinoma who received combination upfront RT and nivolumab, we found the objective response rate (as determined by mRECIST criteria) to be 35%, substantially increased from historical controls, suggesting that this approach may increase the proportion of patients that would benefit from immune checkpoint inhibition.
William Smith, MD of Mount Sinai describes the effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. ________ Among patients with unresectable hepatocellular carcinoma who received combination upfront RT and nivolumab, we found the objective response rate (as determined by mRECIST criteria) to be 35%, substantially increased from historical controls, suggesting that this approach may increase the proportion of patients that would benefit from immune checkpoint inhibition.
Finding May Explain Why Promising Drugs Work – And When They Won’t   CHARLOTTESVILLE, Va., Sept. 26, 2019 – A new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work – and for whom they will fail.  The finding one day could help doctors determine which treatments will be most effective for patients, so that they get the best outcomes.  “Pancreatic cancer is a very difficult problem. It has been a very difficult problem for a long time. The survival for pancreatic cancer patients is very low…
A recent analysis from Canada found that information on health-related quality of life is often not collected for investigational cancer drugs or used to calculate the balance of costs and benefits of these drugs when they are submitted for reimbursement, according to findings published early online in CANCER, a peer-reviewed journal of the American Cancer Society.  Both the effectiveness and the expense of a medication are important in determining its value and whether the cost will be reimbursed. This is often considered in terms of the cost per quality-adjusted life-year (QALY). One QALY equates to one year in perfect health.…
With Breast Cancer Awareness Month Approaching, Cedars-Sinai Experts Discuss New Treatment Options for Early-Stage, Low-Risk Breast Cancer Patients LOS ANGELES (Sept. 24, 2019) — When Jeanne Anderson was diagnosed with breast cancer three years ago, the Beverly Hills resident underwent a course of chemotherapy to shrink the tumors in preparation for surgery. But thanks to a minimally invasive procedure that kills cancer cells by freezing them, she was able to avoid the risks and recovery time of surgery, and she now is cancer-free. Anderson was referred to oncologist Aron Bick, MD, after her gynecologist detected a breast lump in June…
TORONTO, CANADA / ACCESSWIRE / September 24, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today announced that MD Anderson Cancer Center (“MDACC”) has completed enrolment and begun dosing the first cohort of three late-stage pancreatic cancer patients in its investigator-initiated trial of Soricimed’s lead drug candidate, SOR-C13. This trial was launched last month by Principal Investigator, Siqing Fu, MD PhD, a member of the Department of Investigational Cancer Therapeutics at MDACC, one of the world’s most respected cancer research centers. The trial is building on the safety and anticancer activity of SOR-C13 observed in Soricimed’s…
GRACE is very excited to bring to you this new program on supportive care in cancer treatment. Arjun Gupta, MD, one of the GRACE Fellows Ambassador Program Winners for 2019 is the host of this video series, Supportive Care in Cancer Treatment. In this first video, Dr. Gupta’s guest is Charles Loprinzi, MD, with the Mayo Clinic in Rochester, MN. Their topic of discussion is Chemotherapy-induced peripheral neuropathy (CIPN). For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
– Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 – Decision by the European Commission anticipated in fourth quarter of 2019  ROCKLAND, MA and NEW YORK, US, September 20, 2019 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of adult patients with…
Gregory Senofsky, MD of UCLA Health explains the standard conversion rate form lumpectomy to mastectomy. ______ FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate margins and avoiding follow-up surgeries are ongoing challenges. This retrospective, single-institution review found that intraoperative teamwork between a breast cancer surgeon and a dedicated breast pathologist – utilizing tissue-marking ink and gross examination with magnification to evaluate margins – is an accurate, rapid and cost-effective means of significantly reducing the need for second-surgery margin re-excisions or mastectomies. BACKGROUND Several studies have shown significantly increased…
Gregory Senofsky, MD of UCLA Health addresses how reducing the need for second surgery after lumpectomy will affect clinicians today and the next steps. _______ FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate margins and avoiding follow-up surgeries are ongoing challenges. This retrospective, single-institution review found that intraoperative teamwork between a breast cancer surgeon and a dedicated breast pathologist – utilizing tissue-marking ink and gross examination with magnification to evaluate margins – is an accurate, rapid and cost-effective means of significantly reducing the need for second-surgery margin re-excisions…
A majority of patients with cancer don’t understand critical features of the genomic test results they receive when participating in clinical trials, according to a pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP), the first lung cancer precision medicine trial supported by the National Cancer Institute (NCI). In the first-of-its-kind study, researchers surveyed 123 individuals participating in the Lung-MAP trial and other biomarker-driven cancer trials. In these trials, patients receive genomic testing that detects DNA mutations in cancer cells, known as somatic mutations, which are typically found in tumor tissue samples. Precision medicine trials may also include germline testing, which detects inherited…
Gregory Senofsky, MD of UCLA Health answers a question often asked by colleagues. ______ FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate margins and avoiding follow-up surgeries are ongoing challenges. This retrospective, single-institution review found that intraoperative teamwork between a breast cancer surgeon and a dedicated breast pathologist – utilizing tissue-marking ink and gross examination with magnification to evaluate margins – is an accurate, rapid and cost-effective means of significantly reducing the need for second-surgery margin re-excisions or mastectomies. BACKGROUND Several studies have shown significantly increased local breast…
Jonathan Goldman, MD of UCLA Health explains the full trial design of the CASPIAN trial. ______ In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles…
Jonathan Goldman, MD of UCLA Health describes advances in SCLC. _______ In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles of chemotherapy and optional prophylactic…
Jonathan Goldman, MD of UCLA Health answers on the CASPIAN trial: is this practice changing? _______ In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in OS vs. SoC chemotherapy consisting of up to six cycles…
Jonathan Goldman, MD explains IMFINZI is the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer. _______ In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC). IMFINZI in combination with four cycles of standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically-significant and clinically-meaningful improvement in…
Gregory Senofsky, MD of UCLA Health explains the intraoperative teamwork that greatly reduces the need for second surgery after lumpectomy. ____ FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate margins and avoiding follow-up surgeries are ongoing challenges. This retrospective, single-institution review found that intraoperative teamwork between a breast cancer surgeon and a dedicated breast pathologist – utilizing tissue-marking ink and gross examination with magnification to evaluate margins – is an accurate, rapid and cost-effective means of significantly reducing the need for second-surgery margin re-excisions or mastectomies. BACKGROUND Several…
Sudha Amarnath, MD of Cleveland Clinic discusses how this will affect treatment and clinicians today. _____ Preoperative pelvic radiation (XRT), with or without concurrent chemotherapy, is safe and effective in patients with inflammatory bowel disease (IBD) and locally advanced rectal cancer, according to Cleveland Clinic research presented at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting. IBD is a risk factor for the development of rectal cancers, and IBD patients are frequently diagnosed with locally advanced cancers. “Patients who have IBD are at a higher risk of developing rectal cancer compared to the general population, and also tend…
Sudha Amarnath, MD of Cleveland Clinic answers: Is this truly safe? Are these outcomes real? _____ Preoperative pelvic radiation (XRT), with or without concurrent chemotherapy, is safe and effective in patients with inflammatory bowel disease (IBD) and locally advanced rectal cancer, according to Cleveland Clinic research presented at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting. IBD is a risk factor for the development of rectal cancers, and IBD patients are frequently diagnosed with locally advanced cancers. “Patients who have IBD are at a higher risk of developing rectal cancer compared to the general population, and also tend…
Sudha Amarnath, MD of Cleveland Clinic discusses toxicity and efficacy outcomes of preoperative pelvic radiation therapy in patients with inflammatory bowel disease and rectal cancer. ____ Preoperative pelvic radiation (XRT), with or without concurrent chemotherapy, is safe and effective in patients with inflammatory bowel disease (IBD) and locally advanced rectal cancer, according to Cleveland Clinic research presented at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting. IBD is a risk factor for the development of rectal cancers, and IBD patients are frequently diagnosed with locally advanced cancers. “Patients who have IBD are at a higher risk of developing…
New multi-pronged strategy for treating advanced breast cancer earns Breakthrough Award Multifaceted approach combines 3 complementary immunotherapy strategies Two clinical trials slated for 2020 in patients with metastatic breast cancer Platform combines biologic agents to make tumors visible to immune system BUFFALO, N.Y. — A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a U.S. Department of Defense (DoD) grant to Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Rustum Family Professor for Molecular Therapeutics and Translational Research at the Buffalo, N.Y.-based cancer center. The four-year,…
Kailin Yang, MD of Cleveland Clinic answers how this will affect clinicians today and questions asked by his colleagues. _______ Inhibiting two critical steps in the metabolism of glioblastoma stem cells (GSCs) attenuates GSC self-renewal and reduces tumorigenesis, finds a new study presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO). “Determining how to target glioma stem cells effectively has been a major challenge in treating glioblastoma [GBM],†says Kailin Yang, MD, PhD, a radiation oncology resident at Cleveland Clinic Cancer Center who presented the abstract under the supervision of Jeremy Rich, MD, MHS, of…
Kailin Yang, MD of Cleveland Clinic discusses targeting metabolic reprogramming to radiosensitize glioblastoma stem cells. _________ Inhibiting two critical steps in the metabolism of glioblastoma stem cells (GSCs) attenuates GSC self-renewal and reduces tumorigenesis, finds a new study presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO). “Determining how to target glioma stem cells effectively has been a major challenge in treating glioblastoma [GBM],†says Kailin Yang, MD, PhD, a radiation oncology resident at Cleveland Clinic Cancer Center who presented the abstract under the supervision of Jeremy Rich, MD, MHS, of the University of California…
Challenges and Pathways to Coverage, with Christine Cambareri, PharmD, BCPS, BCOP. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO 2019. In this video, the doctors discuss their thoughts on KRAS G12D as a new target. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO 2019. In this video, the doctors discuss stage 4 non small cell lung cancer and new targets, specifically RET. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO 2019. In this video, the doctors discuss stage 4 non small cell lung cancer and new targets, specifically MET. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing series recapping the 2019 ASCO meeting, Drs. Jack West, Charu Aggarwal and Benjamin Levy gather to discuss the long-term effects of Pembrolizumab and how its promising new results may impact yours or a loved one’s cancer treatment. CancerGRACE is funded by our community. If you would like to learn more or donate, please visit CancerGRACE.org. Thank you for watching. If you would like to join the conversation, please visit cancergrace.org/forum to join our community.
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing series recapping the 2019 ASCO meeting, Drs. Jack West, Charu Aggarwal and Benjamin Levy review the results from the Adjuvant Afatinib Trial regarding stages 2 and 3 non-small cell lung cancer treatment. We can’t do what we do without your help. Please visit CancerGRACE.org to donate, find out about volunteer opportunities or learn more about CancerGRACE’s mission to provide the information and support needed to overcome cancer. Thank you for watching. If you would like to join the conversation, please…